Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.

Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C, Hauschild A.

Expert Opin Biol Ther. 2012 Aug;12(8):1087-99. doi: 10.1517/14712598.2012.694421. Epub 2012 Jun 14. Review.

PMID:
22694288
2.

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].

Chiarion-Sileni V, Del Bianco P, Romanini A, Guida M, Paccagnella A, Dalla Palma M, Naglieri E, Ridolfi R, Silvestri B, Michiara M, De Salvo GL.

BMC Cancer. 2006 Feb 27;6:44.

3.

Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.

Loquai C, Nashan D, Hensen P, Luger TA, Grabbe S, Sunderk├Âtter C, Schiller M.

Eur J Dermatol. 2008 Jan-Feb;18(1):29-35. Epub 2007 Dec 18.

PMID:
18086586
4.

The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.

Trinh VA, Zobniw C, Hwu WJ.

Expert Opin Drug Saf. 2017 Aug;16(8):933-940. doi: 10.1080/14740338.2017.1343301. Epub 2017 Jun 30. Review.

PMID:
28627943
5.

Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.

Muggiano A, Mulas C, Fiori B, Liciardi G, Pintus M, Tanca L, Tedde A, Turno R, Desogus A.

Melanoma Res. 2004 Apr;14(2):S1-7.

PMID:
15057049
6.

Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.

Minutilli E, Feliciani C.

Tumori. 2012 Mar-Apr;98(2):185-90. doi: 10.1700/1088.11928. Review.

PMID:
22677983
7.

Adjuvant therapy of cutaneous melanoma: the interferon debate.

Kefford RF.

Ann Oncol. 2003 Mar;14(3):358-65. Review.

PMID:
12598338
8.

Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.

Yamazaki N, Uhara H, Wada H, Matsuda K, Yamamoto K, Shimamoto T, Kiyohara Y.

J Dermatol. 2016 Oct;43(10):1146-1153. doi: 10.1111/1346-8138.13338.

9.

Sylatron: a pegylated interferon for use in melanoma.

Patel JN, Walko CM.

Ann Pharmacother. 2012 Jun;46(6):830-8. doi: 10.1345/aph.1Q791. Epub 2012 May 22. Review.

PMID:
22619474
10.

U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.

Herndon TM, Demko SG, Jiang X, He K, Gootenberg JE, Cohen MH, Keegan P, Pazdur R.

Oncologist. 2012;17(10):1323-8. doi: 10.1634/theoncologist.2012-0123. Epub 2012 Sep 21.

11.

Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.

Dummer R, Garbe C, Thompson JA, Eggermont AM, Yoo K, Maier T, Bergstrom B.

J Clin Oncol. 2006 Mar 1;24(7):1188-94.

PMID:
16505439
12.

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.

Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L.

J Clin Oncol. 2002 Sep 1;20(17):3703-18. Review.

PMID:
12202672
13.

Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.

Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG.

Cancer J. 2000 May-Jun;6(3):139-45.

PMID:
10882328
14.

Adjuvant interferon therapy for malignant melanoma: the debate.

Zhou Q, Zhang XS.

Chin J Cancer. 2010 Nov;29(11):907-13. Review.

15.

Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective.

Rubin KM, Vona K, Madden K, McGettigan S, Braun IM.

Support Care Cancer. 2012 Aug;20(8):1601-11. doi: 10.1007/s00520-012-1473-0. Epub 2012 May 5. Review.

PMID:
22562583
16.

Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.

Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, Pappo A.

Pediatr Blood Cancer. 2016 Jul;63(7):1207-13. doi: 10.1002/pbc.25983. Epub 2016 Apr 1.

17.

Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.

Gogas H, Bafaloukos D, Ioannovich J, Skarlos D, Polyzos A, Fountzilas G, Kalofonos HP, Aravantinos G, Tsoutsos D, Panagiotou P, Frangia K, Petrakopoulou T, Pectasides D; Hellenic Coperative Oncology Group.

Anticancer Res. 2004 May-Jun;24(3b):1947-52.

18.

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M.

J Clin Oncol. 2004 Jan 1;22(1):53-61. Epub 2003 Dec 9.

PMID:
14665609
19.

Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence.

Schachter J, Brenner B, Fenig E, Yahav J, Marshak G, Sulkes A, Gutman H.

Oncol Rep. 1999 Nov-Dec;6(6):1389-93.

PMID:
10523717
20.

Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?

Sondak VK, Kudchadkar R.

Oncologist. 2012;17(10):1223-4. doi: 10.1634/theoncologist.2012-0368. Epub 2012 Sep 21. No abstract available.

Supplemental Content

Support Center